Physician profile
Addison Ritchie
NPI 1558898767
$946.29
in general payments reported to CMS, 2019-2025
16 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.16 · 2023: $204 · 2024: $237 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $167.86 | 2023-2025 | |
| Galderma Laboratories, L.P. | $137.05 | 2024 | |
| Novartis Pharmaceuticals Corporation | $111.26 | 2023-2025 | |
| Amgen INC. | $92.82 | 2023-2025 | Otezla, Otezla |
| Journey Medical Corporation | $74.16 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $62.69 | 2023-2025 | Dupixent |
| Organogenesis INC. | $49.70 | 2024-2025 | Affinity |
| Genzyme Corporation | $49.26 | 2023-2024 | |
| Janssen Biotech, INC. | $45.03 | 2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $33.59 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.76 | 2025 | Sotyktu |
| Lilly USA, LLC | $26.16 | 2025 | Ebglyss |
| Convatec INC. | $25.58 | 2025 | |
| Leo Pharma INC. | $23.33 | 2025 | Anzupgo |
| Pfizer INC. | $16.56 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $2.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Addison Ritchie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.